Hepatic DNA adduct dosimetry in rats fed tamoxifen: a comparison of methods

被引:14
作者
Schild, LJ
Phillips, DH
Osborne, MR
Hewer, A
Beland, FA
Churchwell, MI
Brown, K
Gaskell, M
Wright, E
Poirier, MC
机构
[1] NCI, Carcinogen DNA Interact Sect, NIH, Bethesda, MD 20892 USA
[2] Inst Canc Res, Sutton SM2 5NG, Surrey, England
[3] Natl Ctr Toxicol Res, Div Biochem Toxicol, Jefferson, AR 72079 USA
[4] Univ Leicester, Bioctr, Canc Biomarkers & Prevent Grp, Leicester LE1 7RH, Leics, England
基金
美国国家卫生研究院;
关键词
D O I
10.1093/mutage/gei015
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Liver homogenates from rats fed tamoxifen (TAM) in the diet were shared among four different laboratories. TAM-DNA adducts were assayed by high pressure liquid chromatography-electrospray tandem mass spectrometry (HPLC-ES-MS/MS), TAM-DNA chemiluminescence immunoassay (TAM-DNA CIA), and P-32-postlabeling with either thin layer (P-32-P-TLC) or liquid chromatography (P-32-P-HPLC) separation. In the first study, rats were fed a diet containing 500 p.p.m. TAM for 2 months, and the values for measurements of the (E)-alpha-(deoxyguanosin-N-2-yl)-tamoxifen (dG-N-2-TAM) adduct in replicate rat livers varied by 3.5-fold when quantified using 'in house' TAM-DNA standards, or other approaches where appropriate. In the second study, rats were fed 0, 50, 250 or 500 p.p.m. TAM for 2 months, and TAM-DNA values were quantified using both 'in house' approaches as well as a newly synthesized [N-methyl-H-3]TAM-DNA standard that was shared among all the participating groups. In the second study, the total TAM-DNA adduct values varied by 2-fold, while values for the dG-N-2-TAM varied by 2.5-fold. Ratios of dG-N-2-TAM:(E)-alpha-(deoxyguanosin-N-2-yl)-N-desmethyltamoxifen (dG-N-2-N-desmethyl-TAM) in the second study were similar to 1:1 over the range of doses examined. The study demonstrated a remarkably good agreement for TAM-DNA adduct measurements among the diverse methods employed.
引用
收藏
页码:115 / 124
页数:10
相关论文
共 44 条
[11]   Tamoxifen ('Nolvadex'): a review [J].
Clemons, M ;
Danson, S ;
Howell, A .
CANCER TREATMENT REVIEWS, 2002, 28 (04) :165-180
[12]   Risk of malignant mixed mullerian tumors after tamoxifen therapy for breast cancer [J].
Curtis, RE ;
Freedman, DM ;
Sherman, ME ;
Fraumeni, JF .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2004, 96 (01) :70-74
[13]   Overview of the main outcomes in breast-cancer prevention trials [J].
Cuzick, J ;
Powles, T ;
Veronesi, U ;
Forbes, J ;
Edwards, R ;
Ashley, S ;
Boyle, P .
LANCET, 2003, 361 (9354) :296-300
[14]   Synthesis and investigation of α-hydroxy-N,N-didesmethyltamoxifen as a proximate carcinogen in the metabolic activation of tamoxifen [J].
da Costa, GG ;
Marques, MM ;
Freeman, JP ;
Beland, FA .
CHEMICAL RESEARCH IN TOXICOLOGY, 2003, 16 (09) :1090-1098
[15]   Quantification of tamoxifen DNA adducts using on-line sample preparation and HPLC-electrospray ionization tandem mass spectrometry [J].
da Costa, GG ;
Marques, MM ;
Beland, FA ;
Freeman, JP ;
Churchwell, MI ;
Doerge, DR .
CHEMICAL RESEARCH IN TOXICOLOGY, 2003, 16 (03) :357-366
[16]   DNA adduct formation and mutant induction in Sprague-Dawley rats treated with tamoxifen and its derivatives [J].
da Costa, GG ;
McDaniel-Hamilton, LP ;
Heflich, RH ;
Marques, MM ;
Beland, FA .
CARCINOGENESIS, 2001, 22 (08) :1307-1315
[17]   Characterization of the major DNA adduct formed by α-hydroxy-N-desmethyltamoxifen in vitro and in vivo [J].
da Costa, GG ;
Hamilton, LP ;
Beland, FA ;
Marques, MM .
CHEMICAL RESEARCH IN TOXICOLOGY, 2000, 13 (03) :200-207
[18]  
Davis W, 2000, CANCER RES, V60, P2887
[19]  
Divi RL, 1999, CANCER RES, V59, P4829
[20]   HYDROXY DERIVATIVES OF TAMOXIFEN [J].
FOSTER, AB ;
JARMAN, M ;
LEUNG, OT ;
MCCAGUE, R ;
LECLERCQ, G ;
DEVLEESCHOUWER, N .
JOURNAL OF MEDICINAL CHEMISTRY, 1985, 28 (10) :1491-1497